Related coverage linked through entity extraction aliases.
Jul 15, 2026
Anthropic launched Claude Science, an AI workbench with 60+ skills and databases, and began preclinical programs for neglected diseases. A demo analyzed 100 rare genetic diseases in under an hour.
Jul 31, 2026
Benchmark studies show general-purpose LLMs like GPT-5.2, Gemini 3.1 Pro, and Claude Opus 4.6 outperform FDA-cleared clinical AI tools and physicians on diagnostic reasoning tasks. Domain-adapted LLMs also beat larger generic models on clinical research tasks, while agentic systems show only modest gains. Regulatory clearance pathways have not yet addressed comparative performance.
Jul 03, 2026
Anthropic announced it will run its own preclinical drug-discovery programs for neglected and rare diseases and launched Claude Science, an AI workbench for researchers. The company has not named specific diseases or detailed how it would bring candidates to market.
May 20, 2026
Bristol Myers Squibb will deploy Anthropic’s Claude across global operations, putting the AI platform in the hands of more than 30,000 employees. BMS plans to use it in R&D, clinical development, manufacturing and commercial work.
May 05, 2026
Healthcare AI companies are making bold claims, but many have not brought treatments to market. One article said human testing remains the key measure, citing trial timelines, costs, and current programs.
Apr 16, 2026
Novartis chief executive Vas Narasimhan has joined Anthropic’s board. The appointment adds a pharma executive as Anthropic expands into drug discovery and launches Claude for Life Sciences.
Feb 13, 2026
Isomorphic Labs introduced IsoDDE, a drug discovery engine that outperforms AlphaFold 3 by a factor of two in prediction accuracy. Google also updated Gemini 3 Deep Think, which now outperforms competing models in complex scientific tasks.
